GT Biopharma (GT Biopharma) Short-Term Debt & Capital Lease Obligation : $0.03 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. GT Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.03 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. GT Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

GT Biopharma Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for GT Biopharma's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Short-Term Debt & Capital Lease Obligation Chart

GT Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

13.36

26.33

0.03

0.11

0.06

GT Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.12	0.12	0.09	0.06	0.03

GT Biopharma Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

GT Biopharma Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma (GT Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

OXI1:Germany

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Executives

Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen	director, officer: Exec. Chair. and Interim CEO	LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri	officer: CFO & Secretary	2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel	director	70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk	officer: Pres. of R&D, CMO	HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban	director	1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy	officer: Acting Chief Financial Officer	8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon	director, officer: CFO	7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross	director, officer: Chief Executive Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski	officer: Chief Medical Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith	director, 10 percent owner, officer: CEO	1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman	10 percent owner	224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc	10 percent owner
Bristol Investment Fund Ltd	10 percent owner	89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205